Startseite The evaluation of melatonin and EGF interaction on breast cancer metastasis
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The evaluation of melatonin and EGF interaction on breast cancer metastasis

  • Moloud Akbarzadeh , Vahid Vahedian , Zahraa Hamid Abudulmohesen , Parvin Ghadimi , Nazila Fathi Maroufi EMAIL logo , Ali Farzaneh , Sepideh Bastani , Neda Roshanravan , Abbas Pirpour Tazehkand , Amir Fattahi , Yousef Faridvand , Mehdi Talebi , Davoud Farajzadeh EMAIL logo und Maryam Akbarzadeh EMAIL logo
Veröffentlicht/Copyright: 23. Juli 2024
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Objectives

Metastasis in breast cancer is the first cause of death in patients. The epidermal growth factor (EGF) increases cancer cells’ invasion, and migration. Melatonin’s inhibitory effects on various types of cancer were confirmed. This study aimed to investigate whether melatonin could apply its impact through the EGF-related pathways or not.

Methods

First, MDA-MB-231 and MCF7 cells were cultured, and then melatonin effects on cell viability were determined by MTT assay. Transwell invasion assay was applied to identify the invasiveness of these breast cancer cell lines under treatment of EGF and melatonin. Real-time RT-PCR then investigated the expression of MMP9 and MMP2 in determined groups. Cell proliferation was also assayed under EGF and melatonin treatment using Ki67 assessment by flow cytometry.

Results

The rate of invasion and migration of EGF-treated cells increased in both groups, in which melatonin caused increased invasion by EGF just in MCF7 cells. MMP9 and MMP2 expression increased significantly in both cell lines under EGF treatment, and melatonin increased these genes’ expression in both cell lines (p<0.05). EGF increased the MMP9 and MMP2 gene expression, and melatonin increased EGF-induced expression (p<0.05). The EGF reduced the expression of the Ki67 protein in the MCF7 cell line, which was negatively affected by melatonin and EGF. In contrast, along with melatonin, EGF did not affect the proliferation of the MDA-MB-231 cell line.

Conclusions

The results of this study show that melatonin in the presence of EGF does not show the anti-cancer properties previously described for this substance.


Corresponding authors: Nazila Fathi Maroufi, Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, E-mail: ; and Davoud Farajzadeh, Department of Cellular and Molecular Biology, Faculty of Biological Science, Azarbaijan Shahid Madani University, Tabriz, Iran, E-mail: ; and Maryam Akbarzadeh, Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran, E-mail:

Acknowledgments

This work supported by Department of Biochemistry, Erasmus University Medical Center, Rotterdam, the Netherlands.

  1. Research ethics: The local Institutional Review Board deemed the study exempt from review.

  2. Informed consent: Not applicable.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Competing interests: Authors state no conflict of interest.

  5. Research funding: None.

  6. Data availability: Not applicable.

References

1. Maroufi, NF, Rashidi, M, Vahedian, V, Jahanbazi, R, Mostafaei, S, Akbarzadeh, M, et al.. Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line. Breast Cancer 2021:1–14. https://doi.org/10.1007/s12282-021-01310-4.Suche in Google Scholar PubMed

2. Rashidi, M, Bazi, A, Amani, D, Jamshidi, H, Ziai, SA, editors. Umbelliprenin efficiently induces complete pathologic response in 4T1 tumor-bearing Balb/c mice. In: Proceedings for annual meeting of the Japanese pharmacological society WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology). Kyoto: Japanese Pharmacological Society; 2018.10.1254/jpssuppl.WCP2018.0_PO4-6-28Suche in Google Scholar

3. Shiran, MR, Mahmoudian, E, Ajami, A, Hosseini, SM, Khojasteh, A, Rashidi, M, et al.. Effect of Auraptene on angiogenesis in xenograft model of breast cancer. Horm Mol Biol Clin Invest 2022;43:7–14. https://doi.org/10.1515/hmbci-2021-0056.Suche in Google Scholar PubMed

4. Woodburn, J. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–50. https://doi.org/10.1016/s0163-7258(98)00045-x.Suche in Google Scholar PubMed

5. Normanno, N, De Luca, A, Bianco, C, Strizzi, L, Mancino, M, Maiello, MR, et al.. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2–16. https://doi.org/10.1016/j.gene.2005.10.018.Suche in Google Scholar PubMed

6. Motaghi, E, Pirbalooti, MG, Bozorgi, H, Eslami, M, Rashidi, M. Safety and efficacy of dexmedetomidine in breast surgeries: a systematic review and meta-analysis. J PeriAnesthesia Nurs 2021;36:179–86. https://doi.org/10.1016/j.jopan.2020.09.011.Suche in Google Scholar PubMed

7. Jeong, Y-J, Choi, Y, Shin, J-M, Cho, H-J, Kang, J-H, Park, K-K, et al.. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem Toxicol 2014;68:218–25. https://doi.org/10.1016/j.fct.2014.03.022.Suche in Google Scholar PubMed

8. Seshacharyulu, P, Ponnusamy, MP, Haridas, D, Jain, M, Ganti, AK, Batra, SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15–31. https://doi.org/10.1517/14728222.2011.648617.Suche in Google Scholar PubMed PubMed Central

9. Faskhoudi, MA, Molaei, P, Sadrkhanloo, M, Orouei, S, Hashemi, M, Bokaie, S, et al.. Molecular landscape of c-Myc signaling in prostate cancer: a roadmap to clinical translation. Pathol Res Pract 2022:153851. https://doi.org/10.1016/j.prp.2022.153851.Suche in Google Scholar PubMed

10. Choi, J, Moon, SY, Hong, JP, Song, J-y, Oh, KT, Lee, S-w. Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines. Cancer Invest 2010;28:505–14. https://doi.org/10.3109/07357900902783179.Suche in Google Scholar PubMed

11. Rashidi, M, Ahmadzadeh, A, Ziai, SA, Narenji, M, Jamshidi, H. Evaluating cytotoxic effect of nanoliposomes encapsulated with umbelliprenin on 4T1 cell line. In Vitro Cell Dev Biol Anim 2017;53:7–11. https://doi.org/10.1007/s11626-016-0080-7.Suche in Google Scholar PubMed

12. Amani, D, Shakiba, E, Motaghi, E, Alipanah, H, Jalalpourroodsari, M, Rashidi, M. Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice. Horm Mol Biol Clin Invest 2022;43:71–9. https://doi.org/10.1515/hmbci-2021-0028.Suche in Google Scholar PubMed

13. Li, H, Qiu, Z, Li, F, Wang, C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett 2017;14:5865–70. https://doi.org/10.3892/ol.2017.6924.Suche in Google Scholar PubMed PubMed Central

14. Maroufi, NF, Amiri, M, Dizaji, BF, Vahedian, V, Akbarzadeh, M, Roshanravan, N, et al.. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells. Eur J Pharmacol 2020:173282. https://doi.org/10.1016/j.ejphar.2020.173282.Suche in Google Scholar PubMed

15. Akbarzadeh, M, Movassaghpour, AA, Ghanbari, H, Kheirandish, M, Maroufi, NF, Rahbarghazi, R, et al.. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. Sci Rep 2017;7:17062. https://doi.org/10.1038/s41598-017-16940-y.Suche in Google Scholar PubMed PubMed Central

16. Akbarzadeh, M, Movassaghpour, AA, Ghanbari, H, Kheirandish, M, Maroufi, NF, Rahbarghazi, R, et al.. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. Sci Rep 2017;7:1–11. https://doi.org/10.1038/s41598-017-16940-y.Suche in Google Scholar

17. Maroufi, NF, Vahedian, V, Hemati, S, Rashidi, M, Akbarzadeh, M, Zahedi, M, et al.. Targeting cancer stem cells by melatonin: effective therapy for cancer treatment. Pathol Res Pract 2020:152919. https://doi.org/10.1016/j.prp.2020.152919.Suche in Google Scholar PubMed

18. Pourmohammad, P, Maroufi, NF, Rashidi, M, Vahedian, V, Pouremamali, F, Faridvand, Y, et al.. Potential therapeutic effects of melatonin mediate via miRNAs in cancer. Biochem Genet 2021:1–23. https://doi.org/10.1007/s10528-021-10104-4.Suche in Google Scholar PubMed

19. Sonehara, NM, Lacerda, JZ, Jardim-Perassi, BV, de Paula, JR, Moschetta-Pinheiro, MG, Souza, YST, et al.. Melatonin regulates tumor aggressiveness under acidosis condition in breast cancer cell lines. Oncol Lett 2019;17:1635–45. https://doi.org/10.3892/ol.2018.9758.Suche in Google Scholar PubMed PubMed Central

20. Srinivasan, V, Spence, DW, Pandi-Perumal, SR, Trakht, I, Cardinali, DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008;7:189–203. https://doi.org/10.1177/1534735408322846.Suche in Google Scholar PubMed

21. Hill, SM, Belancio, VP, Dauchy, RT, Xiang, S, Brimer, S, Mao, L, et al.. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015;22:R183–204. https://doi.org/10.1530/erc-15-0030.Suche in Google Scholar PubMed PubMed Central

22. Cos, S, Fern, R, Mediavilla, M. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003;10:153–9. https://doi.org/10.1677/erc.0.0100153.Suche in Google Scholar PubMed

23. Cos, S, Blask, DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res 1994;17:25–32. https://doi.org/10.1111/j.1600-079x.1994.tb00110.x.Suche in Google Scholar PubMed

24. Blask, DE, Sauer, LA, Dauchy, RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113–32. https://doi.org/10.2174/1568026023394407.Suche in Google Scholar PubMed

25. Dznelashvili, N, Kasradze, D, Tavartkiladze, A. Expression of epidermal growth factor receptor and concentrations of epidermal growth factor and melatonin in endometrial carcinoma. Georgian Med News 2014:17–24.Suche in Google Scholar

26. Entezari, M, Sadrkhanloo, M, Rashidi, M, Asnaf, SE, Taheriazam, A, Hashemi, M, et al.. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022:103680. https://doi.org/10.1016/j.critrevonc.2022.103680.Suche in Google Scholar PubMed

27. Rashidi, M, Ziai, SA, Zanjani, TM, Khalilnezhad, A, Jamshidi, H, Amani, D. Umbelliprenin is potentially toxic against the HT29, CT26, MCF-7, 4T1, A172, and GL26 cell lines, potentially harmful against bone marrow-derived stem cells, and non-toxic against peripheral blood mononuclear cells. Iran Red Crescent Med J 2016;18. https://doi.org/10.5812/ircmj.35167.Suche in Google Scholar PubMed PubMed Central

28. Vickers, NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol 2017;27:R713–5. https://doi.org/10.1016/j.cub.2017.05.064.Suche in Google Scholar PubMed

29. Shiran, MR, Amani, D, Ajami, A, Jalalpourroodsari, M, Khalizadeh, M, Rashidi, M. Antitumor effects of Auraptene in 4T1 tumor-bearing Balb/c mice. Horm Mol Biol Clin Invest 2021;42:245–52. https://doi.org/10.1515/hmbci-2020-0090.Suche in Google Scholar PubMed

30. Ahmadian, S, Sabzichi, M, Rashidi, M, Mohammadian, J, Mahmoudi, S, Maroufi, NF, et al.. Sensitization of A-549 lung cancer cells to Cisplatin by Quinacrine-loaded lipidic nanoparticles via suppressing Nrf2 mediated defense mechanism. N Schmied Arch Pharmacol 2021;394:1521–8. https://doi.org/10.1007/s00210-021-02079-1.Suche in Google Scholar PubMed

31. Sabzichi, M, Oladpour, O, Mohammadian, J, Rashidi, M, Hosseinzadeh, M, Mardomi, A, et al.. Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepG2 cancer cells. N Schmied Arch Pharmacol 2021;394:2429–39. https://doi.org/10.1007/s00210-021-02164-5.Suche in Google Scholar PubMed

32. Khalilnezhad, A, Mahmoudian, E, Mosaffa, N, Anissian, A, Rashidi, M, Amani, D. Effects of Chlorella vulgaris on tumor growth in mammary tumor-bearing Balb/c mice: discussing association of an immune-suppressed protumor microenvironment with serum IFNγ and IgG decrease and spleen IgG potentiation. Eur J Nutr 2018;57:1025–44. https://doi.org/10.1007/s00394-017-1387-1.Suche in Google Scholar PubMed

33. Kim, K, Wu, H-G, Jeon, S-R. Epidermal growth factor-induced cell death and radiosensitization in epidermal growth factor receptor-overexpressing cancer cell lines. Anticancer Res 2015;35:245–53.Suche in Google Scholar

34. Song, J-y, Lee, S-w, Hong, JP, Chang, SE, Choe, H, Choi, J. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett 2009;283:135–42. https://doi.org/10.1016/j.canlet.2009.03.034.Suche in Google Scholar PubMed

35. Koul, HK, Pal, M, Koul, S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013;4:342–59. https://doi.org/10.1177/1947601913507951.Suche in Google Scholar PubMed PubMed Central

36. Kocyigit, A, Guler, EM, Karatas, E, Caglar, H, Bulut, H. Dose-dependent proliferative and cytotoxic effects of melatonin on human epidermoid carcinoma and normal skin fibroblast cells. Mutat Res Genet Toxicol Environ Mutagen 2018;829:50–60. https://doi.org/10.1016/j.mrgentox.2018.04.002.Suche in Google Scholar PubMed

37. Jiang, W, Cheng, Y, Zhao, N, Li, L, Shi, Y, Zong, A, et al.. Sulfated polysaccharide of Sepiella Maindroni ink inhibits the migration, invasion and matrix metalloproteinase-2 expression through suppressing EGFR-mediated p38/MAPK and PI3K/Akt/mTOR signaling pathways in SKOV-3 cells. Int J Biol Macromol 2018;107:349–62. https://doi.org/10.1016/j.ijbiomac.2017.08.178.Suche in Google Scholar PubMed

38. Elbaz, M, Nasser, MW, Ravi, J, Wani, NA, Ahirwar, DK, Zhao, H, et al.. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol 2015;9:906–19. https://doi.org/10.1016/j.molonc.2014.12.010.Suche in Google Scholar PubMed PubMed Central

39. Zhang, Q, Liu, G, Wu, Y, Sha, H, Zhang, P, Jia, J. BDNF promotes EGF-induced proliferation and migration of human fetal neural stem/progenitor cells via the PI3K/Akt pathway. Molecules 2011;16:10146–56. https://doi.org/10.3390/molecules161210146.Suche in Google Scholar PubMed PubMed Central

40. Price, JT, Tiganis, T, Agarwal, A, Djakiew, D, Thompson, EW. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 1999;59:5475–8.Suche in Google Scholar

41. Maroufi, NF, Vahedian, V, Mazrakhondi, SAM, Kooti, W, Khiavy, HA, Bazzaz, R, et al.. Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism. N Schmied Arch Pharmacol 2020;393:1–11. https://doi.org/10.1007/s00210-019-01692-5.Suche in Google Scholar PubMed

42. Maroufi, NF, Rashidi, MR, Vahedian, V, Akbarzadeh, M, Fattahi, A, Nouri, M. Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance. Life Sci 2020;241:117106. https://doi.org/10.1016/j.lfs.2019.117106.Suche in Google Scholar PubMed

43. Fathi Maroufi, N, Taefehshokr, S, Rashidi, M-R, Taefehshokr, N, Khoshakhlagh, M, Isazadeh, A, et al.. Vascular mimicry: changing the therapeutic paradigms in cancer. Mol Biol Rep 2020:1–17. https://doi.org/10.1007/s11033-020-05515-2.Suche in Google Scholar PubMed

44. Dahl, KDC, Symowicz, J, Ning, Y, Gutierrez, E, Fishman, DA, Adley, BP, et al.. Matrix metalloproteinase 9 is a mediator of epidermal growth factor–dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 2008;68:4606–13. https://doi.org/10.1158/0008-5472.can-07-5046.Suche in Google Scholar

45. Majumder, A, Ray, S, Banerji, A. Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells. Mol Cell Biochem 2019;452:111–21. https://doi.org/10.1007/s11010-018-3417-6.Suche in Google Scholar PubMed

Received: 2023-12-01
Accepted: 2024-07-12
Published Online: 2024-07-23

© 2024 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 30.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hmbci-2023-0082/html?lang=de
Button zum nach oben scrollen